Get the Stockscreener App
193.40
2.87%
5.39
Pre-market:
199.84
6.44
+3.33%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $193.40, with a volume of 2.73M.
It is up +2.87% in the last 24 hours and up +104.33% over the past month.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
See More
Previous Close:
$188.01
Open:
$194.02
24h Volume:
2.73M
Relative Volume:
0.44
Market Cap:
$299.82B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
64.22
EPS:
3.0115
Net Cash Flow:
$9.87B
1W Performance:
+4.93%
1M Performance:
+104.33%
6M Performance:
+162.95%
1Y Performance:
+166.17%
1-Day Range:
$190.60
$195.90
1-Week Range:
$186.32
$195.90
52-Week Range:
$61.24
$195.90
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
193.40 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
LLY
Lilly Eli Co
|
1,025.00 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.35 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
222.44 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
158.20 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
China charges former AstraZeneca executive - Financial Times
AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials - Clinical Trials Arena
Astrazeneca re-doses $80bn annual sales goal - marketscreener.com
AstraZeneca Earnings Call Highlights Growth And Pipeline - TipRanks
AstraZeneca Q4 Earnings Call Highlights - Yahoo Finance
AstraZeneca: Q4 Earnings AnalysisTicks The Boxes, Upgrading To Buy (AZN) - Seeking Alpha
AstraZeneca Q4 and FY 2025 slides: 8% revenue growth, strategic investments for 2030 By Investing.com - Investing.com South Africa
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials - TechTarget
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
AstraZeneca Keeps Its Growth Engine Moving Amid Rising Costs - Kalkine Media
Market Voices: Paramount-WBD bid, Holtec IPO, AstraZeneca - Seeking Alpha
Why Is AstraZeneca Stock Gaining Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
Relaxin unrest after Astrazeneca phase II HF bid joins failures - BioWorld MedTech
Oakmark International Strategy Updates Portfolio, Adds AstraZene - GuruFocus
AstraZeneca bets on continued oncology demand for 2026 growth - Pharmaceutical Technology
Jim Cramer on AstraZeneca: "We Want Every Drug Stock" - Finviz
Jim Cramer on AstraZeneca: “We Want Every Drug Stock” - Yahoo Finance
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity - Citeline News & Insights
AstraZeneca profits boosted by strong cancer drug sales - Investors' Chronicle
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026 - FinancialContent
AstraZeneca stock hits all-time high at 194.18 USD By Investing.com - Investing.com India
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook - TradingView
AstraZeneca stock hits all-time high at 194.18 USD - Investing.com
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings - Yahoo! Finance Canada
AstraZeneca PLC $AZN Shares Sold by Foresight Group Ltd Liability Partnership - MarketBeat
Oppenheimer Asset Management Inc. Increases Position in AstraZeneca PLC $AZN - MarketBeat
Earnings call transcript: AstraZeneca’s Q4 2025 revenue grows 8%, stock rises - Investing.com
AstraZeneca Targets Global Obesity Market With Low-Cost Weight-Loss Drugs - Bloomberg.com
AstraZeneca (AZN) Exceeds Revenue Expectations with Strong Growt - GuruFocus
Earnings snapshot: AstraZeneca beats Q4 revenue estimates; initiates FY outlook - MSN
ProShare Advisors LLC Has $50.24 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca rises as cancer drugs power Q4 beat (AZN:NYSE) - Seeking Alpha
AstraZeneca forecasts steady growth in 2026 on cancer drug demand, hikes dividend - The Globe and Mail
AstraZeneca (AZN) Projects Revenue Growth and Core Tax Rate Outl - GuruFocus
AstraZeneca Upbeat on Growth as 2025 Profit, Revenue Rise Amid 'Excellent' Pipeline Delivery - Yahoo Finance UK
AstraZeneca’s growth engine stays on track despite cost pressures - Yahoo Finance
AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update - marketscreener.com
AstraZeneca profit jumps as cancer drug sales grow - Yahoo Finance UK
AstraZeneca (Q4 Results): steady progress - Hargreaves Lansdown
AstraZeneca sees further growth, lifted by cancer drugs - The Edge Malaysia
AstraZeneca PLC Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
AstraZeneca Sees Further Growth, Lifted by Cancer Drugs - Bloomberg.com
AstraZeneca profits surge 40% on strong demand for cancer treatments - business-live.co.uk
Trending tickers: TSMC, Oracle, AstraZeneca, Kering and Tui - Yahoo Finance UK
Astrazeneca Q4 Core Earnings, Revenue Rise; Full-Year Outlook Set -- Shares Up Pre-Bell - marketscreener.com
FTSE 100 falls as BP slide outweighs AstraZeneca - marketscreener.com
AstraZeneca profits jump by 40% amid strong demand for cancer drugs - Yahoo Finance UK
FTSE 100 today: Index slips as BP halts buyback; AstraZeneca, Barclays in focus - Investing.com UK
Strong cancer drug sales boost AstraZeneca earnings - Financial Times
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):